COU-AA-302: what clinicians are saying
abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer · NCT00887198 ↗ · Phase 3 · Janssen Research & Development, LLC
One speaker reads COU-AA-302 as supporting abiraterone through chemotherapy deferral but would probably choose enzalutamide for simpler treatment, while considering abiraterone for high falls risk. A medical oncologist sees a clear survival advantage as reshaping care previously centered on docetaxel; the first speaker finds the final survival gain smaller than expected. That treatment preference is not demonstrated superiority: the cross-trial discussion cannot establish relative benefit, and prednisone's anticancer dose effect remains unresolved.
Created with AI · how we check it
- edition 1
- commentary checked Nov 14, 2026
- 266 verified statements
This edition $1,250, with MCP access for your AI agent. Get this report
11 findings, and what sits behind each
01. One speaker would probably favor enzalutamide for uncomplicated mCRPC, while preserving reasons to consider abiraterone
1 of 7 cited clinicians · 23 statements from 2 speakers in 5 sources, 4 of them podcasts or videos · 16 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Population and setting.
02. One speaker reads cross-trial results as numerically favoring enzalutamide over abiraterone; commentary weighs population, endpoint, steroid-control and crossover caveats.
No named clinician · accounts and unnamed speakers · 13 statements from 1 speaker in 2 sources, all podcasts or videos · 10 passages
Limitations recorded: 2.
Draws on: The comparison, Design and conduct, Primary endpoint: Overall Survival, Population and setting.
03. Speakers regard pre-chemotherapy abiraterone as a major advance, but differ in how strongly they describe its survival value
4 of 7 cited clinicians · 20 statements from 4 speakers in 7 sources, 3 of them podcasts or videos · 19 passages
Limitations recorded: 2.
Draws on: Primary endpoint: Overall Survival, Population and setting, Primary endpoint: Radiographic Progression-free Survival (rPFS), Design and conduct, Secondary endpoints, The comparison.
04. Speakers give symptom control and chemotherapy deferral substantial clinical weight
2 of 7 cited clinicians · 10 statements from 4 speakers in 8 sources, 2 of them podcasts or videos · 12 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, Primary endpoint: Overall Survival, Primary endpoint: Radiographic Progression-free Survival (rPFS), Design and conduct, Population and setting.
05. Whether reducing prednisone improves the abiraterone trade-off remains an open question in one podcast exchange
No named clinician · accounts and unnamed speakers · 18 statements in 3 sources, 2 of them podcasts or videos · 8 passages
Limitations recorded: 2.
Draws on: Safety and tolerability, The comparison.
06. One safety interview offers strong long-term reassurance, while other discussions emphasize patient-specific risks
No named clinician · accounts and unnamed speakers · 17 statements from 1 speaker in 6 sources, 3 of them podcasts or videos · 13 passages
Limitations recorded: 2.
Draws on: Safety and tolerability.
07. Speakers see oral abiraterone as widening treatment opportunity; one X account questions the cost of earlier use
3 of 7 cited clinicians · 12 statements from 3 speakers in 6 sources, 4 of them podcasts or videos · 10 passages
Limitations recorded: 2.
Draws on: Population and setting, Primary endpoint: Overall Survival, Primary endpoint: Radiographic Progression-free Survival (rPFS), Secondary endpoints, Design and conduct.
08. One X account finds prior-local-therapy analyses reassuring, but not evidence of a causal survival gain
1 of 7 cited clinicians · 6 statements from 1 speaker in 3 sources · 6 passages
Limitations recorded: 2.
09. A podcast speaker and an X account discourage serial ARPI use; the episode separates intolerance from progression
1 of 7 cited clinicians · 22 statements from 2 speakers in 4 sources, 1 of them a podcast or video · 16 passages
Limitations recorded: 2.
10. One speaker favors enzalutamide–radium-223, while one X account relays no OS benefit for a different intensification approach
1 of 7 cited clinicians · 5 statements from 2 speakers in 3 sources, 1 of them a podcast or video · 3 passages
Limitations recorded: 2.
Draws on: Population and setting.
11. A discussion weighs androgen biology, one prolonged abiraterone response and unvalidated selection hypotheses; a publication reports benefit across ERG groups without statistically significant differential benefit.
No named clinician · accounts and unnamed speakers · 20 statements in 2 sources, 1 of them a podcast or video · 15 passages
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 11
1 of 7 cited clinicians
One speaker would probably favor enzalutamide for uncomplicated mCRPC, while preserving reasons to consider abiraterone
23 statements from 2 speakers in 5 sources, 4 of them podcasts or videos
- 23
- statements
- 16
- passages
- 5
- sources
- 2
- speakers
What the statements areViews 17Questions and uncertainty 3Clinical experience 1Comparisons 2Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 25Giving context 6Recorded with the findingLimitations: 3
1 post or article · 4 podcasts and video
Draws on: Safety and tolerability, Population and setting.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
The full report also has 4 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.
Abbreviations (5)
ARPI, androgen receptor pathway inhibitor; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival.
The full COU-AA-302 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What clinical or biological features do clinicians say could guide choosing abiraterone acetate plus prednisone rather than enzalutamide in COU-AA-302’s asymptomatic or mildly symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer setting without prior ARPI exposure, beyond comorbidities and tolerability?
From finding F1 (23 statements from 2 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 120commentary sources screened
- 37sources cited by verified statements
- 18named in screened sources
- 17speakers cited in the report
- 12cited speakers with a verified identity
7 cited clinicians, speakers with a confirmed clinical role, of them 7 physicians. By role and specialty:
- 5 physician, Medical oncology
- 2 physician, Radiation oncology
Also in the sources: 2 organizational or shared accounts, not counted as people.
- 266verified statements, each linked to its source
- 19of them from speakers with a confirmed clinical role
- 11findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 17 sections | Paid |
| Verified statements with short source quotes and links | 266 | Paid |
| Who said each statement: the cited speakers | 17 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 12 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 37 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
14 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Overall Survival | 9 | 6 |
| Primary endpoint: Radiographic Progression-free Survival (rPFS) | 5 | 3 |
| Secondary endpoints | 7 | 5 |
| Population and setting | 13 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 10 | 3 |
| Safety and tolerability | 17 | 3 |
| Design and conduct | 9 | 3 |
| First-line choice, comorbidity and patient burden | 25 | 5 |
| Prednisone's physiological and anticancer roles | 17 | 2 |
| Chemotherapy alternatives, treatment opportunity and cost | 13 | 6 |
| Prior local therapy and interpretation of subgroup associations | 4 | 2 |
| Exposure-defined pathways, progression and intolerance exceptions | 8 | 3 |
| Alternative combinations and regimen-specific bone protection | 5 | 3 |
| Development experience, exceptional response and predictive biology | 15 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
266 verified statements from 37 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 108 statements · 41%from 7 videos and episodes · about 15 per source | ||||
| YouTube | 17 | 3 | 3 | |
| X videos | 4 | 2 | 2 | |
| Podcasts | 87 | 2 | 2 | |
| Posts · 20 statements · 7%from 15 posts · about 1 per source | ||||
| X threads | 20 | 15 | 113 | |
| Primary sources · 138 statements · 52%cited for context, not screened · from 15 sources · about 9 per source | ||||
| Publications | 138 | 15 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 16 / quarter
- Screened window
- Jun 11, 2012 → Sep 14, 2026
- Cited window
- Aug 9, 2012 → Sep 14, 2026
- Retrieved
- Nov 14, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Registry
- NCT00887198
- Study IDs
- CR016927 · COU-AA-302 (Janssen Research & Development, LLC) · 2008-008004-41
- Sponsor
- Janssen Research & Development, LLC
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Completed
- Enrollment
- 1,088 actual
- Registered
- 2009-04-23
- Start
- 2009-04-28 actual
- Primary completion
- 2014-03-31 actual
- Primary endpoints
- Overall Survival
- Radiographic Progression-free Survival (rPFS)
- Interventions
- 3 registered
More on: Prostate cancer, abiraterone acetate
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on distinguishing newer androgen receptor inhibitors from first-generation agents when considering abiraterone alternatives in castration-resistant prostate cancer; a view on androgen receptor pathway inhibition versus chemotherapy in metastatic castration-resistant prostate cancer after androgen deprivation alone; a view on prednisone’s potential benefits and harms in interpreting abiraterone trial controls and cross-trial comparisons; a view on antiandrogen therapy’s place among systemic treatment options for metastatic castration-resistant prostate cancer; a view on crossover and secondary outcomes when weighing alternative therapy in chemotherapy-naive metastatic castration-resistant prostate cancer.
- 149 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 45 sources about other trials or topics are not included.
Show all 14 known gaps +Fewer −
- These sources are not a representative sample of HCP opinion. Source totals, reposts and nested relays cannot be interpreted as independent-clinician counts or consensus.
- Several spoken passages cannot be assigned to a named participant. They are attributed to their episode or discussion and are not counted as separate people.
- The PREVAIL comparison is incompletely represented, including crossover, subsequent-treatment, chemotherapy-delay, quality-of-life and skeletal-event context.
- The available account of an ongoing prednisone analysis and suggested negative aspect does not fully support characterization of its evidence or ownership.
- Coverage of comments about alternatives to ARPI monotherapy, later-line treatment options and earlier antiandrogen evidence is incomplete. The options described here should not be read as everything discussed in those exchanges.
- No separate protocol was available. Full text was unavailable for the rPFS-biomarker and initial-Gleason-score papers, limiting assessment of their detailed methods and qualifications.
- Discussion that does not name COU-AA-302 or uses different terminology may be missing. Absence from this edition does not establish absence from public discussion.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Cross-trial comparisons, historical controls, retrospective subgroups, early-phase research and individual patient experiences are preserved as such; none establishes head-to-head superiority or a validated new treatment-selection rule.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 14, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. COU-AA-302 (NCT00887198): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 14, 2026. https://www.erudio.com/reports/cou-aa-302-nct00887198
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "COU-AA-302" (NCT00887198), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "cou-aa-302-nct00887198". If you cannot make requests, read https://www.erudio.com/reports/cou-aa-302-nct00887198.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT00887198", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT00887198 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/cou-aa-302-nct00887198.json
curl https://www.erudio.com/reports/cou-aa-302-nct00887198.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "cou-aa-302-nct00887198" })release b55fc20f9baf6d7817a6572753ca86076512ff46e10bd28b5a33895f4833d2cb
Questions
How much does the COU-AA-302 report cost?
One edition costs $1,250 (Standard · 266 verified statements · 19 from 7 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the COU-AA-302 report cover?
266 statements from 37 sources (2 podcasts, 5 videos, 15 posts, 15 papers), 19 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 14, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the COU-AA-302 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "cou-aa-302-nct00887198" }) previews it and create_order({ "report": "cou-aa-302-nct00887198", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the COU-AA-302 report?
Edition 1 (version 1.0.0), accepted Nov 14, 2026 UTC; last checked for new commentary Nov 14, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.